期刊文献+

阿瑞匹坦用于肺腺癌紫杉醇联合顺铂化疗引起恶心呕吐的临床研究 被引量:2

Clinical research on aprepitant for the prevention of nausea and vomiting due to paclitaxel and cisplatin chemotherapy in lung adenocarcinoma patients
暂未订购
导出
摘要 目的 观察阿瑞匹坦在肺腺癌紫杉醇联合顺铂方案化疗中的急性期及延迟期止吐疗效和安全性。方法 50例肺腺癌患者,均接受紫杉醇联合顺铂的TP方案化疗,随机分为实验组及对照组,每组25例。对照组患者接受5-HT3受体拮抗剂托烷司琼、地塞米松预防止吐,实验组在对照组基础上联合应用阿瑞匹坦预防止吐。完成1个周期化疗后,评估两组患者在化疗后急性期及延迟期恶心呕吐情况及不良反应。结果 50例患者均按期完成1个周期的TP方案化疗,实验组和对照组急性恶心、呕吐完全缓解率(CR)分别为44%和32%(χ~2=0.764,P〉0.05),有效率(RR)分别为80%和72%(χ~2=0.439,P〉0.05),差异无统计学意义。实验组和对照组延迟性恶心呕吐CR分别为52%和24%(χ~2=4.160,P〈0.05),RR分别为76%和44%(χ~2=5.333,P〈0.05),差异有统计学意义。两组患者不良反应主要包括头晕、乏力、呃逆、腹胀、便秘,均为轻度,差异无统计学意义。结论阿瑞匹坦联合托烷司琼、地塞米松方案预防肺腺癌紫杉醇联合顺铂化疗引起的急性期及延迟期恶心呕吐疗效确切,安全性高,值得临床进一步应用推广。 Objective To observe the acute and delayed antiemetic effects and safety of aprepitant for the prevention of paclitaxel and cisplatin chemotherapy-induced nausea and vomiting in lung adenocarcinoma carcinoma patients. Methods Fifty patients with lung adenocarcinoma carcinoma were randomly divided into the experimental group and control group ,25 cases in each group. All the patients in the two groups received TP regimen chemotherapy (paclitaxel and cisplatin). The antiemetic regimen for control group was 5-HT3 receptor antagonist tropisetron and dexamethasone;the regimen for experimental group consisted of aprepitant, tropisetron and dexamethasone. The acute and delayed antiemetic effects and adverse effects were evaluated after 1 cycle chemotherapy. Results All 50 patients completed 1 cycle chemotherapy, the CR rates of acute antiemetic effect in experimental group and control group were 44% and 32% , there was no significant difference between the two groups (X2 = 0. 764, P 〉 0. 05 ) ; the RR rates of acute an- tiemetic effect in experimental group and control group were 80% and 72% ,there was no difference between the two groups (X2 = 0. 439, P 〉 0. 05 ) ; the CR rates of delayed antiemetic effect in experimental group and control group were 52% and 24% ,there were statistical difference between the two groups (X2 =4. 160,P 〈0. 05) ;the RR rates of delayed antiemetic effect in experimental group and control group were 76% and 44% , there was no difference between the two groups (X2 = 5. 333, P 〉 0. 05 ). The adverse effects mainly included dizziness, fatigue, hiccups, bloating and constipation, there was no statistical difference between the two groups. Conclusion Aprepitant combined with tropise- tron and dexamethasone has better antiemetic effects on the prevention of nausea and vomiting due to paclitaxel and cisplatin chemotherapy in lung adenocarcinoma patients,it is worth to be popularized.
出处 《实用药物与临床》 CAS 2016年第9期1152-1155,共4页 Practical Pharmacy and Clinical Remedies
关键词 阿瑞匹坦 肺腺癌 紫杉醇 顺铂 化疗 恶心 呕吐 Aprepitant Lung adenocarcinoma carcinoma Paclitaxel Cisplalin Chemotherapy Nausea and vomiting
  • 相关文献

参考文献5

二级参考文献89

  • 1Jordan K,Sippel C,Schmoll H J,et al.Guidelines for Antiemetic Treatment of Chemotherapy-Induced Nausea and Vomiting:Past,Present,and Future Recommendations[J].Oncologist,2007,12 (9):1143-1150.
  • 2Ballatori E,Roila F,Ruggeri B,et al.The impact of chemotherapy-induced nausea and vomiting on health-related quality of life[J].Supportive Care in Cancer,2007,15 (2):179-185.
  • 3Grunberg S M,Deuson R R,Mavros P,et al.Incidence of chemotherapy-induced nausea and emesis after modern antiemetics?[J].Cancer,2004,100 (10):2261-2268.
  • 4Aziz N M.Cancer survivorship research:State of knowledge,challenges and opportunities[J].Acta Oncol,2007,46 (4):417-432.
  • 5Gralla R,Linchinister M,Vegt S V,et al.Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy:results of a double-blind randomized phase Ⅲ trial comparing single doses of palonosetron with ondansetron[J]Ann Oncol,2003,14 (10):1570-1577.
  • 6Eisenberg P,Figueroa-Vadillo J,Zamora R,et al.Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron,a pharmacologically novel 5-HT3 receptor antagonist[J].Cancer,2003,98 (11):2473-2482.
  • 7Rapoport B L,Jordan K,Boice J A,et al.Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types:a randomized,double-blind study[J].Support Care Cancer,2010,18 (4):423-431.
  • 8Hargreaves R.Imaging Substance P Receptors (NK1) in the Living Human Brain Using Positron Emission Tomography[J].J Clin Psychiatry,2002,63 (suppl 11):18-24.
  • 9Griffin AM,Butow PN,Coates AS,et al.On the receiving end.Ⅴ:Patient perceptions of the side effects of cancer chemotherapy in 1993[J].Ann Oncol,1996,7(2):189-195.
  • 10Ballatori E,Roila F,Ruggeri B,et al.The impact of chemotherapyinduced nausea and vomiting on health-related quality of life[J].Support Care Cancer,2007,15:179-185.

共引文献71

同被引文献8

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部